Eva Vargas

Eva Vargas

Auto-generated profile, based on publicly available information

Eva Vargas

Department of Nanoengineering, University of California San Diego, La Jolla, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2023 in Nature Reviews Endocrinology
Verified
Journal Article
Open access
PDF file
EVEva Vargas
Eva Vargas
PNPonnusamy Nandhakumar
Ponnusamy Nandhakumar
Shichao DingShichao Ding
Shichao Ding
TSTamoghna Saha
Tamoghna Saha
Joseph WangJoseph Wang
Joseph Wang
Tremendous progress has been made towards achieving tight glycaemic control in individuals with diabetes mellitus through the use of frequent or continuous glucose measurements. However, in patients who require insulin, accurate dosing must consider multiple factors that affect insulin sensitivity and modulate insulin bolus needs. Accordingly, an urgent need exists for frequent and real-time insulin measurements to closely track the dynamic blood concentration of insulin during insulin therapy and guide optimal insulin dosing. Nevertheless, traditional centralized insulin testing cannot offer timely measurements, which are essential to achieving this goal. This Perspective discusses the advances and challenges in moving insulin assays from traditional laboratory-based assays to frequent and continuous measurements in decentralized (point-of-care and home) settings. Technologies that hold promise for insulin testing using disposable test strips, mobile systems and wearable real-time insulin-sensing devices are discussed. We also consider future prospects for continuous insulin monitoring and for fully integrated multisensor-guided closed-loop artificial pancreas systems.

16 November 2020 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
PDF file
KWKelilah L. Wolkowicz
Kelilah L. Wolkowicz
EAEleonora Maria Aiello
Eleonora Maria Aiello
EVEva Vargas
Eva Vargas
HTHazhir Teymourian
Hazhir Teymourian
FTFarshad Tehrani
Farshad Tehrani
EDEyal Dassau
Eyal Dassau
As wearable healthcare monitoring systems advance, there is immense potential for biological sensing to enhance the management of type 1 diabetes (T1D). The aim of this work is to describe the ongoing development of biomarker analytes in the context of T1D. Technological advances in transdermal biosensing offer remarkable opportunities to move from research laboratories to clinical point‐of‐care applications. In this review, a range of analytes, including glucose, insulin, glucagon, cortisol, lactate, epinephrine, alcohol, as well as ketones such as beta‐hydroxybutyrate (BOHB), will be evaluated to determine the current status and research direction of those analytes specifically relevant to T1D management, using both in‐vitro and on‐body detection. Understanding state‐of‐the‐art developments in biosensing technologies will aid in bridging the gap from bench‐to‐clinic T1D analyte measurement advancement.

26 August 2021 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
VMVíctor Ruiz-Valdepeñas Montiel
Víctor Ruiz-Valdepeñas Montiel
JSJuliane R. Sempionatto
Juliane R. Sempionatto
EVEva Vargas
Eva Vargas
EBEileen Bailey
Eileen Bailey
JMJennifer May
Jennifer May
Joseph WangJoseph Wang
Joseph Wang